openFDA
Cure8 regulatory brief
Dexamethasone Intensol FDA label update (2026-08-21)
Medications
Corticosteroids
Steroids
Anemia
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Why This Matters
This is the official FDA label text for dexamethasone, so it clarifies approved uses and gives practical dosing and tapering guidance. It explicitly names "regional enteritis and ulcerative colitis," which matters to people with Crohn's disease or ulcerative colitis considering steroid treatment for acute flares.
Who Should Pay Attention
Adults with Crohn's disease or ulcerative colitis, pediatric patients (and their caregivers) when steroid dosing is considered, and clinicians who prescribe or manage corticosteroid therapy in IBD.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
The updated label is a regulatory/drug-label record — it summarizes approved uses and practical dosing information rather than reporting new clinical trial results.
For people with Crohn's disease or ulcerative colitis, the label notes corticosteroids like dexamethasone can be used to "tide the patient over a critical period" but does not position them as maintenance therapy; the label emphasizes individualized dosing, gradual withdrawal after long-term therapy, and variable dosing for pediatric patients.
For clinicians and patients, the label also reiterates typical equivalent dosing relationships among corticosteroids and gives example acute dosing schedules and parenteral dosing for specific situations (e.g., cerebral edema).
It lists many organ-system indications and standard corticosteroid precautions that may be relevant when weighing steroid use in IBD flares.
Keep In Mind
This record is a regulatory drug label (Dailymed/NLM) that summarizes approved indications and general dosing/precautions. It is not a clinical trial report or new efficacy evidence. Corticosteroids are generally used for induction/acute control, not maintenance, and have well-known systemic side effects that require clinician oversight.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorSportpharm LLC
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedAug 21, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Prednisone FDA label update (2026-07-31)
Prednisone is a commonly used systemic steroid for short-term control of IBD flares; label updates affect dosing, warnings, and official approved uses that patients and clinicians rely on.
Prednisone FDA label update (2026-08-20)
Prednisone is commonly used short-term in IBD flares; an FDA label update clarifies approved uses and dosing considerations that affect how clinicians prescribe it and how patients should take and stop the drug.
Dexamethasone FDA label update (2026-07-07)
This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...